Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia-A randomized controlled trial
© 2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC..
OBJECTIVE: Treatment of frontal fibrosing alopecia (FFA) is complicated and challenging. In this study, we evaluated the efficacy of combining topical tacrolimus with isotretinoin versus finasteride in patients with FFA.
METHODOLOGY: Thirty-one patients with FFA were divided randomly into two groups. Therapeutic regimen of the first group (group A, n = 16) was isotretinoin and tacrolimus (Capsule isotretinoin 20 mg daily and topical tacrolimus 0.1% BD). The second group (group B, n = 15) was given finasteride and tacrolimus (Tablet finasteride 2.5 mg daily and topical tacrolimus 0.1% BD). Patients were treated and followed up periodically for 12 weeks. Evaluation of the treatment efficacy was based on Patient Global Assessment and Physician Global Assessment scales. Objective evaluation was based on improving the severity of skin lesions by viewing serial images taken from the affected areas.
RESULTS: Physician Global Assessment (PGA) was significantly better in the group A as compared with the group B at 4 weeks (p = 0.038). Physician satisfaction in the group A was better than the group B at 12 weeks, but this was not statistically significant (p > 0.05). Patient Global Assessment and patient satisfaction in the group A was better than the group B at 8 and 12 weeks, but it was not statistically significant (p > 0.05).
CONCLUSION: Although both therapeutic regimens were effective in the treatment of FFA, treatment with tacrolimus and isotretinoin is significantly more effective than tacrolimus and finasteride.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of cosmetic dermatology - 22(2023), 2 vom: 28. Feb., Seite 613-619 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rokni, Ghasem Rahmatpour [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
57GNO57U7G |
|---|
| Anmerkungen: |
Date Completed 13.02.2023 Date Revised 13.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jocd.15232 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343363909 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343363909 | ||
| 003 | DE-627 | ||
| 005 | 20231226020256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jocd.15232 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343363909 | ||
| 035 | |a (NLM)35815916 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rokni, Ghasem Rahmatpour |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia-A randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.02.2023 | ||
| 500 | |a Date Revised 13.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC. | ||
| 520 | |a OBJECTIVE: Treatment of frontal fibrosing alopecia (FFA) is complicated and challenging. In this study, we evaluated the efficacy of combining topical tacrolimus with isotretinoin versus finasteride in patients with FFA | ||
| 520 | |a METHODOLOGY: Thirty-one patients with FFA were divided randomly into two groups. Therapeutic regimen of the first group (group A, n = 16) was isotretinoin and tacrolimus (Capsule isotretinoin 20 mg daily and topical tacrolimus 0.1% BD). The second group (group B, n = 15) was given finasteride and tacrolimus (Tablet finasteride 2.5 mg daily and topical tacrolimus 0.1% BD). Patients were treated and followed up periodically for 12 weeks. Evaluation of the treatment efficacy was based on Patient Global Assessment and Physician Global Assessment scales. Objective evaluation was based on improving the severity of skin lesions by viewing serial images taken from the affected areas | ||
| 520 | |a RESULTS: Physician Global Assessment (PGA) was significantly better in the group A as compared with the group B at 4 weeks (p = 0.038). Physician satisfaction in the group A was better than the group B at 12 weeks, but this was not statistically significant (p > 0.05). Patient Global Assessment and patient satisfaction in the group A was better than the group B at 8 and 12 weeks, but it was not statistically significant (p > 0.05) | ||
| 520 | |a CONCLUSION: Although both therapeutic regimens were effective in the treatment of FFA, treatment with tacrolimus and isotretinoin is significantly more effective than tacrolimus and finasteride | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cicatricial alopecia | |
| 650 | 4 | |a finasteride | |
| 650 | 4 | |a frontal fibrosing alopecia | |
| 650 | 4 | |a isotretinoin | |
| 650 | 4 | |a tacrolimus | |
| 650 | 7 | |a Finasteride |2 NLM | |
| 650 | 7 | |a 57GNO57U7G |2 NLM | |
| 650 | 7 | |a Isotretinoin |2 NLM | |
| 650 | 7 | |a EH28UP18IF |2 NLM | |
| 650 | 7 | |a Tacrolimus |2 NLM | |
| 650 | 7 | |a WM0HAQ4WNM |2 NLM | |
| 700 | 1 | |a Emadi, Seyed Naser |e verfasserin |4 aut | |
| 700 | 1 | |a Dabbaghzade, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Jahantigh, Neda |e verfasserin |4 aut | |
| 700 | 1 | |a Beyzaee, Amir Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Aseem |e verfasserin |4 aut | |
| 700 | 1 | |a Rudnicka, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Goldust, Mohamad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cosmetic dermatology |d 2002 |g 22(2023), 2 vom: 28. Feb., Seite 613-619 |w (DE-627)NLM166816639 |x 1473-2165 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:2 |g day:28 |g month:02 |g pages:613-619 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jocd.15232 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 2 |b 28 |c 02 |h 613-619 | ||